1. Reg-2, A Downstream Signaling Protein in the Ciliary Neurotrophic Factor Survival Pathway, Alleviates Experimental Autoimmune Encephalomyelitis
- Author
-
Shu Han, Hong Jiang, Beibei Wang, Fan Zhang, and Ke-Wei Tian
- Subjects
0301 basic medicine ,Neuroscience (miscellaneous) ,Axonal loss ,Ciliary neurotrophic factor ,multiple sclerosis ,lcsh:RC321-571 ,lcsh:QM1-695 ,experimental autoimmune encephalitis ,Reg-2 ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Parenchyma ,CNTF ,medicine ,neuronal protection ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Gene ,Neuroinflammation ,Original Research ,biology ,Multiple sclerosis ,Experimental autoimmune encephalomyelitis ,lcsh:Human anatomy ,medicine.disease ,Cell biology ,Electrophysiology ,030104 developmental biology ,biology.protein ,Anatomy ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Ciliary neurotrophic factor (CNTF), originally described as a neurocytokine that could support the survival of neurons, has been recently found to alleviate demyelination, prevent axon loss, and improve functional recovery in a rat model of acute experimental autoimmune encephalomyelitis (EAE). However, poor penetration into the brain parenchyma and unfavorable side effects limit the utility of CNTF. Here, we evaluated the therapeutic potential of a protein downstream of CNTF, regeneration gene protein 2 (Reg-2). Using multiple morphological, molecular biology, and electrophysiological methods to assess neuroinflammation, axonal loss, demyelination, and functional impairment, we observed that Reg-2 and CNTF exert similar effects in the acute phase of EAE. Both treatments attenuated axonal loss and demyelination, improved neuronal survival, and produced functional improvement. With a smaller molecular weight and improved penetration into the brain parenchyma, Reg-2 may be a useful substitute for CNTF therapy in EAE and multiple sclerosis (MS).
- Published
- 2016